TABLE 5.
Management of asthmatic patients with COVID-19
| Management | Treatment received | Patients# n |
| Oxygen | 30 (81) | 37 |
| Antibiotic(s) | 31 (84) | 37 |
| Azithromycin | 16 (52) | 37 |
| Intravenous or oral corticosteroids for asthma exacerbation during hospitalisation | 1 (3) | 37 |
| SABA prescription | 31 (86) | 36 |
| pMDI plus spacer chamber | 29 (81) | 36 |
| DPI | 2 (6) | 36 |
| Nebulised | 4 (11) | 36 |
| Asthma controller treatment adjustment | ||
| Maintenance | 33 (94) | 35 |
| Stepped up | 1 (3) | 35 |
Data are presented as n (%), unless otherwise stated. SABA: short-acting β-agonist; pMDI: pressurised metered-dose inhaler; DPI: dry powder inhaler. #: patients with available information.